×
About 207,410 results

ALLMedicine™ Heart Failure Center

Research & Reviews  97,393 results

Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident H...
https://doi.org/10.1016/j.jacc.2020.07.044
Journal of the American College of Cardiology; Suthahar N, Lau ES et. al.

Sep 18th, 2020 - Whether cardiovascular (CV) disease risk factors and biomarkers associate differentially with heart failure (HF) risk in men and women is unclear. The purpose of this study was to evaluate sex-specific associations of CV risk factors and biomarker...

Long-term outcomes after reoperation for mitral paravalvular leaks: a single-centre exp...
https://doi.org/10.1093/ejcts/ezaa331
European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery; Yajima S, Fukushima S et. al.

Sep 18th, 2020 - We aimed to analyse the pathology of paravalvular leak (PVL), and determine the long-term outcomes of redo mitral valve replacement and risk factors of all-cause mortality. Seventy-nine patients (mean age 70 ± 9 years; 54 female, 68%) who underwen...

Outcomes of diuretics in rheumatic heart disease with compensated chronic heart failure...
https://doi.org/10.1002/ehf2.12987
ESC Heart Failure References; Liu C, Lai Y et. al.

Sep 18th, 2020 - The purpose of this retrospective propensity score-matched study was to evaluate the superiority of different application approaches [continuous diuretics use (CDU) vs. intermittent diuretics use (IDU)] and types [loop diuretics (LDs) vs. thiazide...

Efficacy of early initiation of ivabradine treatment in patients with acute heart failu...
https://doi.org/10.1002/ehf2.12997
ESC Heart Failure References; Su Y, Ma T et. al.

Sep 18th, 2020 - Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to ...

Edge-to-edge tricuspid valve repair for severe tricuspid regurgitation 20 years after c...
https://doi.org/10.1002/ehf2.12992
ESC Heart Failure References; Misumida N, Steidley DE et. al.

Sep 18th, 2020 - Tricuspid valve regurgitation in orthotopic heart transplant recipients is common. Surgical corrections have been the mainstay of the treatment for diuretic-refractory heart failure due to severe tricuspid regurgitation. However, post-transplant p...

see more →

Guidelines  295 results

Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study
https://www.journal-of-cardiology.com/article/S0914-5087(20)30271-9/fulltext
Journal of Cardiology; Kwak S

Aug 25th, 2020 - Patients with heart failure (HF) are more at risk of developing cancer than the general population.

2019 AATS/ACC/SCAI/STS expert consensus systems of care document: Operator and institut...
https://doi.org/10.1016/j.jtcvs.2019.12.001
The Journal of Thoracic and Cardiovascular Surgery; , Bonow RO et. al.

Jun 16th, 2020 - 2019 AATS/ACC/SCAI/STS expert consensus systems of care document: Operator and institutional recommendations and requirements for transcatheter mitral valve intervention: A joint report of the American Association for Thoracic Surgery, the America...

Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314099
European Heart Journal; Anker SD, Butler J et. al.

Jun 4th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, ...

Meeting News From ACC 2020
https://www.healio.com/cardiology/meeting-news/acc-meeting
Cardiology Today;

Apr 1st, 2020 - The latest news from the ACC Annual Scientific Session, with physician perspective, researcher interviews and clinician insight on cardiovascular prevention, heart failure and more.

Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician
https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician
American Heart Association;

Mar 16th, 2020 - As the global impact of COVID-19 rises, the scientific community continues to evaluate the clinical impact and health care needs of patients with cardiovascular disease, who are at increased risk for serious complications with COVID-19. Together, ...

see more →

Drugs  2,485 results see all →

Clinicaltrials.gov  102,357 results

Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident H...
https://doi.org/10.1016/j.jacc.2020.07.044
Journal of the American College of Cardiology; Suthahar N, Lau ES et. al.

Sep 18th, 2020 - Whether cardiovascular (CV) disease risk factors and biomarkers associate differentially with heart failure (HF) risk in men and women is unclear. The purpose of this study was to evaluate sex-specific associations of CV risk factors and biomarker...

Long-term outcomes after reoperation for mitral paravalvular leaks: a single-centre exp...
https://doi.org/10.1093/ejcts/ezaa331
European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery; Yajima S, Fukushima S et. al.

Sep 18th, 2020 - We aimed to analyse the pathology of paravalvular leak (PVL), and determine the long-term outcomes of redo mitral valve replacement and risk factors of all-cause mortality. Seventy-nine patients (mean age 70 ± 9 years; 54 female, 68%) who underwen...

Outcomes of diuretics in rheumatic heart disease with compensated chronic heart failure...
https://doi.org/10.1002/ehf2.12987
ESC Heart Failure References; Liu C, Lai Y et. al.

Sep 18th, 2020 - The purpose of this retrospective propensity score-matched study was to evaluate the superiority of different application approaches [continuous diuretics use (CDU) vs. intermittent diuretics use (IDU)] and types [loop diuretics (LDs) vs. thiazide...

Efficacy of early initiation of ivabradine treatment in patients with acute heart failu...
https://doi.org/10.1002/ehf2.12997
ESC Heart Failure References; Su Y, Ma T et. al.

Sep 18th, 2020 - Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to ...

Edge-to-edge tricuspid valve repair for severe tricuspid regurgitation 20 years after c...
https://doi.org/10.1002/ehf2.12992
ESC Heart Failure References; Misumida N, Steidley DE et. al.

Sep 18th, 2020 - Tricuspid valve regurgitation in orthotopic heart transplant recipients is common. Surgical corrections have been the mainstay of the treatment for diuretic-refractory heart failure due to severe tricuspid regurgitation. However, post-transplant p...

see more →

News  4,717 results

Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study
https://www.journal-of-cardiology.com/article/S0914-5087(20)30271-9/fulltext
Journal of Cardiology; Kwak S

Aug 25th, 2020 - Patients with heart failure (HF) are more at risk of developing cancer than the general population.

Roche's combo therapy for advanced breast cancer gets U.S. FDA approval
https://www.reuters.com/article/us-roche-hldg-fda/roches-combo-therapy-for-advanced-breast-cancer-gets-u-s-fda-approval-idUSKBN240297

Jun 29th, 2020 - (Reuters) - The U.S. Food and Drug Administration on Monday approved Roche Holding AG’s combination therapy for a form of advanced breast cancer that has spread to other parts of the body. The therapy, Phesgo, was approved for patients with HER2-p...

FDA approves emergency use of Abiomed heart pump for COVID-19 patients
https://www.reuters.com/article/us-health-coronavirus-abiomed/fda-approves-emergency-use-of-abiomed-heart-pump-for-covid-19-patients-idUSKBN2382F3

Jun 1st, 2020 - (Reuters) - Abiomed Inc said on Monday the U.S. Food and Drug Administration has granted emergency use authorization for its temporary invasive heart pump to help patients suffering from COVID-19 related right heart failure. The device, Impella RP...

AstraZeneca diabetes drug gets U.S. nod to treat heart failure
https://www.reuters.com/article/us-astrazeneca-fda/astrazeneca-diabetes-drug-gets-u-s-nod-to-treat-heart-failure-idUSKBN22I0MM

May 6th, 2020 - (Reuters) - AstraZeneca’s diabetes drug Farxiga has become the first in its class to win U.S. approval as a treatment for heart failure, opening up a major new market opportunity outside of the medicine’s established field. FILE PHOTO: The company...

Meeting News From ACC 2020
https://www.healio.com/cardiology/meeting-news/acc-meeting
Cardiology Today;

Apr 1st, 2020 - The latest news from the ACC Annual Scientific Session, with physician perspective, researcher interviews and clinician insight on cardiovascular prevention, heart failure and more.

see more →

Patient Education  163 results see all →